Targeting specific proteins to treat acute myelogenous leukemia
Precision Targeting of Myeloid Src-family Kinases in Acute Myelogenous Leukemia
This study is looking at a new treatment for acute myelogenous leukemia (AML) using a special drug called TL02-59 that targets cancer cells, and it aims to see how well it works and if there are any challenges in using it, with the hope of finding a better way to help patients like you.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-10687861 on NIH RePORTER |
What this research studies
This research focuses on a new treatment approach for acute myelogenous leukemia (AML) by using a small molecule inhibitor that targets specific proteins involved in cancer cell growth. The study investigates how this inhibitor, known as TL02-59, affects the proliferation of leukemia cells and aims to understand its effectiveness and potential resistance mechanisms. Patients' bone marrow samples are analyzed to determine their sensitivity to the treatment, and the research includes testing the drug in animal models to assess its efficacy in eliminating leukemia cells. The goal is to develop a targeted therapy that could improve outcomes for patients with AML.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who have been diagnosed with acute myelogenous leukemia.
Not a fit: Patients with other types of leukemia or those who are not adults may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective treatment option for patients with acute myelogenous leukemia.
How similar studies have performed: Previous research has shown promise in targeting tyrosine kinases for treating various cancers, indicating potential success for this novel approach.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Smithgall, Thomas E. — University of Pittsburgh at Pittsburgh
- Study coordinator: Smithgall, Thomas E.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.